IONS: Leerink Raises Target
Leerink Partners raises Ionis Pharmaceuticals' price target to $129 and maintains Outperform rating
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ: IONS ) with a Outperform and raises the price target from $122 to $129.